Helminth egg derivatives as proregenerative immunotherapies

Abstract

The immune system is increasingly recognized as an important regulator of tissue repair. We developed a regenerative immunotherapy from the helminth Schistosoma mansoni soluble egg antigen (SEA) to stimulate production of interleukin (IL)-4 and other type 2-associated cytokines without negative infection-related sequelae. The regenerative SEA (rSEA) applied to a murine muscle injury induced accumulation of IL-4-expressing T helper cells, eosinophils, and regulatory T cells and decreased expression of IL-17A in gamma delta (γδ) T cells, resulting in improved repair and decreased fibrosis. Encapsulation and controlled release of rSEA in a hydrogel further enhanced type 2 immunity and larger volumes of tissue repair. The broad regenerative capacity of rSEA was validated in articular joint and corneal injury models. These results introduce a regenerative immunotherapy approach using natural helminth derivatives.

Document Details

Document Type
Pub Defense Publication
Publication Date
Feb 13, 2023
Source ID
10.1073/pnas.2211703120

Entities

People

  • Alexander F. Chin
  • Alexis N. Peña
  • Amy E. Anderson
  • Christopher Mejia
  • Cynthia A. Berlinicke
  • David R Maestas
  • Don Zack
  • Drew M Pardoll
  • Edward J. Pearce
  • Erika Moore
  • Franck Housseau
  • Helen Hieu Nguyen
  • Hong Zhang
  • J. Woo
  • James I Andorko
  • Jennifer Elisseeff
  • Jin Han
  • Joscelyn C. Mejías
  • Joshua S. T. Hooks
  • Kavita Krishnan
  • Liam Chung
  • Liang Zhao
  • Marie Eric
  • Ronak J. Mahatme
  • Sean H Kelly
  • Sudipto Ganguly
  • Sven D. Sommerfeld
  • Xiaokun Wang
  • Younghwan Choi

Organizations

  • Bloomberg L.P.
  • Johns Hopkins University
  • National Eye Institute
  • National Institutes of Health
  • United States Department of Defense
  • University of Florida

Tags

Fields of Study

  • Medicine

Readers

  • Immunology
  • Immunology and Pathology
  • Marine Ecological Systems Migration

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech